resolving practice barriers to consolidative immunotherapy in stage iii nsclc
Published 5 months ago • 12 plays • Length 5:30Download video MP4
Download video MP3
Similar videos
-
4:30
consolidative immunotherapy in unresectable stage iii nsclc with oncogenic drivers
-
5:30
optimizing consolidative immunotherapy in unresectable stage iii nsclc: case discussion
-
6:20
immunotherapy in stage iii nsclc: practice-changing results of pacific trial (bmic-006)
-
6:00
immunotherapy approaches in unresectable stage iii nsclc: what’s on the horizon?
-
7:44
immunotherapy in stage iii nsclc
-
4:30
consolidative immunotherapy following scrt vs rt only in stage iii nsclc
-
7:44
immunotherapy in stage iii nsclc
-
1:01:46
advancing the frontier: novel immunotherapies for breast cancer treatment
-
9:57
practical considerations for immunotherapy in stage 3 nsclc
-
1:13
immunotherapy in stage iii nsclc metastatic disease
-
![[lung]the role of durvalumab in patients with stage 3 lung cancer in a real hospital](https://i.ytimg.com/vi/EwpYIgllxqY/mqdefault.jpg)
3:53
[lung]the role of durvalumab in patients with stage 3 lung cancer in a real hospital
-
3:05
nsclc: consolidation immunotherapy in practice
-
2:34
dr. langer on practice-changing pacific data in stage iii nsclc
-
1:11:21
maximizing the potential of immunotherapy in unresectable stage iii nsclc
-
55:59
leveraging immunotherapy and egfr targeted treatment in unresectable stage iii nsclc
-
1:00
combining sabr and immunotherapies for nsclc
-
2:20
dr. antonia on investigational immunotherapy combinations in stage iii nsclc
-
3:12
concurrent chemoradiotherapy in stage iii nsclc